Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence

References

• Abou-Donia MB. (1976). Physiological effects and metabolism of gossypol. Residue Rev 61:125–60
   PubMedGoogle Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–20
   PubMed Web of Science ®Google Scholar
• Bowers WF, Fulton S, Thompson J. (1984). Ultrafiltration versus equilibrium dialysis for determination of free fraction. Clin Pharmacokinet 9:49–60
   PubMed Web of Science ®Google Scholar
• Brauer RW. (1959). Mechanisms of bile secretion. J Am Med Assoc 169:1462–6
   PubMed Web of Science ®Google Scholar
• Castro-Perez JM. (2007). Current and future trends in the application of HPLC-MS to metabolite-identification studies. Drug Discov Today 12:249–56
   PubMed Web of Science ®Google Scholar
• Chen J, Lin H, Hu M. (2003). Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther 304:1228–35
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Klaassen CD. (2006). Structure, function, expression, genomic organization and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP) and ABCG2 (BCRP) efflux transporters. J Toxicol 25:231–59
   Google Scholar
• Court MH. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104–16
   PubMed Web of Science ®Google Scholar
• Coutinho EM. (2002). Gossypol: a contraceptive for men. Contraception 65:259–63
   PubMed Web of Science ®Google Scholar
• Cummings J, Zelcer N, Allen JD, et al. (2004). Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 67:31–9
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724–6
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu X, Jia X, et al. (2005). Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr Drug Metab 6:455–68
   PubMed Web of Science ®Google Scholar
• Jia L, Coward LC, Kerstner-Wood CD, et al. (2008). Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother Pharmacol 61:63–73
   PubMed Web of Science ®Google Scholar
• Johnson DA, Amidon GL. (1988). Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J Theor Biol 131:93–106
   PubMed Web of Science ®Google Scholar
• Keshmiri-Neghab H, Goliaei B. (2014). Therapeutic potential of gossypol: an overview. Pharm Biol 52:124–8
   Google Scholar
• Kilpatrick GJ, Smith TW. (2005). Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 25:521–44
   PubMed Web of Science ®Google Scholar
• Levine WG. (1978). Biliary excretion of drugs and other xenobiotics. Annu Rev Pharmacol Toxicol 18:81–96
   PubMed Web of Science ®Google Scholar
• Lian J, Ni Z, Dai X, et al. (2012). Sorafenib sensitizes (−)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Mol Cancer Ther 11:416–26
   PubMed Web of Science ®Google Scholar
• Liu GZ. (1987). Clinical studies of gossypol as a male contraceptive. Reproduction 5:189–92
   Google Scholar
• Liu W, Liu H, Sun H, et al. (2013). Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2013.853849
   Google Scholar
• Mackenzie PI, Bock KW, Burchell B, et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677–85
   PubMed Web of Science ®Google Scholar
• Madan J, Chawla G, Arora V, et al. (2005). Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J 7:E224–30
   PubMed Web of Science ®Google Scholar
• Manevski N, Yli-Kauhaluoma J, Finel M. (2012). UDP-glucuronic acid binds first and the aglycone substrate binds second to form a ternary complex in UGT1A9-catalyzed reactions, in both the presence and absence of bovine serum albumin. Drug Metab Dispos 40:2192–203
   PubMed Web of Science ®Google Scholar
• Miller DL. (1971). Rat small intestine: development, composition and effects of perfusion. Am J Dig Dis 16:247–54
   PubMedGoogle Scholar
• Murakami T, Takano M. (2008). Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4:923–39
   PubMed Web of Science ®Google Scholar
• Othman MA, Abou-Donia MB. (1988). Pharmacokinetic proWle of (±)-gossypol in male Sprague-Dawley rats following single intravenous and oral and subchronic oral administration. Proc Soc Exp Biol Med 188:17–22
   PubMedGoogle Scholar
• Pacifici GM, Viani A. (1992). Methods of determining plasma and tissue binding of drugs: pharmacokinetic consequences. Clin Pharmacokinet 23:449–68
   PubMed Web of Science ®Google Scholar
• Polsky B, Segal SJ, Baron PA, et al. (1989). Inactivation of human immunodeficiency virus in vitro by gossypol. Contraception 39:579–87
   PubMed Web of Science ®Google Scholar
• Razakantoanina V, Nguyen Kim PP, Jaureguiberry G. (2000). Antimalarial activity of new gossypol derivatives. Parasitol Res 86:665–8
   PubMed Web of Science ®Google Scholar
• Riddick DS, Lee C, Ramji S, et al. (2005). Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33:1083–96
   PubMed Web of Science ®Google Scholar
• Ritter JK. (2000). Roles of glucuronidation and UDP glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171–93
   PubMed Web of Science ®Google Scholar
• Rollins DE, Klaassen CD. (1979). Biliary excretion of drugs in man. Clin Pharmacokinet 4:368–79
   PubMed Web of Science ®Google Scholar
• Soderquist R, Bates DJ, Danilov AV, Eastman A. (2013). Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Leukemia 227:2262–4
   Google Scholar
• Wang J, Jin L, Li X, et al. (2013). Gossypol induces apoptosis in ovarian cancer cells through oxidative stress. Mol Biosyst 9:1489–97
   PubMed Web of Science ®Google Scholar
• Wang X, Howell CP, Chen F, et al. (2009). Gossypol: a polyphenolic compound from cotton plant. Adv Food Nutr Res 58:215–63
   PubMedGoogle Scholar
• Wang Y, Lonard DM, Yu Y, et al. (2011). Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol 25:2041–53
   PubMed Web of Science ®Google Scholar
• Wells PG, Mackenzie PI, Chowdhury JR, et al. (2004). Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32:281–90
   PubMed Web of Science ®Google Scholar
• Wong FY, Liem N, Xie C, et al. (2012). Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. PLoS One 7:e50786
   PubMed Web of Science ®Google Scholar
• Wu B, Kulkarni K, Basu S, et al. (2011). First-pass metabolism via UDP-glucuronosyl transferase: a barrier to oral bioavailability of phenolics. J Pharm Sci 100:3655–81
   PubMed Web of Science ®Google Scholar
• Tang L, Singh R, Liu Z, Hu M. (2009). Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Mol Pharm 6:1466–82
   PubMed Web of Science ®Google Scholar
• Wu B. (2012). Pharmacokinetic interplay of phase II metabolism and transport: a theoretical study. J Pharm Sci 101:381–93
   PubMed Web of Science ®Google Scholar
• Wu DF, Yu YW, Tang ZM, Wang MZ. (1986). Pharmacokinetics of (+/−)-, (+)-, and (−)-gossypol in humans and dogs. Clin Pharmacol Ther 39:613–18
   PubMed Web of Science ®Google Scholar
• Xie C, Zhong D, Yu K, Chen X. (2012). Recent advances in metabolite identification and quantitative bioanalysis by LC-Q-TOF MS. Bioanalysis 4:937–59
   PubMed Web of Science ®Google Scholar
• Xu H, Kulkarni KH, Singh R, et al. (2009). Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 6:1703–15
   PubMed Web of Science ®Google Scholar
• Yang X, Gandhi YA, Duignan DB, Morris ME. (2009). Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J 11:511–25
   PubMed Web of Science ®Google Scholar
• Yang X, Gandhi YA, Morris ME. (2010). Biliary excretion in dogs: evidence for a molecular weight threshold. Eur J Pharm Sci 40:33–7
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhu W, Gao S, et al. (2012). Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab Dispos 40:1883–93
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, et al. (2006). Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319:459–67
   PubMed Web of Science ®Google Scholar
• Zhang NR, Yu S, Tiller P, et al. (2009). Quantitation of small molecules using high-resolution accurate mass spectrometers – a different approach for analysis of biological samples. Rapid Commun Mass Spectrom 23:1085–94
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Huang XF, Mu SJ, et al. (2010). Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (−)-gossypol. Asian J Androl 12:390–9
   PubMed Web of Science ®Google Scholar
• Zhou J, Tracy TS, Remmel RP. (2010). Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38:431–40
   PubMed Web of Science ®Google Scholar